PharmaStrategies is committed to building strong partnerships with our clients since 2006. We continue to impact cost savings and innovation in the area of Supply Chain Management while working closely with our clients’ current vendors.
Overcoming A Client’s Comparator Drug Financial Constraints
Our Client encountered significant budgetary issues surrounding the funding of Sutent for an open-label comparator drug trial. Our Client was faced with having to either substantially reduce the number of Subjects in the trial or significantly reduce the rate of enrollment over the 30-month period.
PharmaStrategies provided the Client with an itemized line item financial forecast that illustrated eliminating out-of-pocket cost for each Subject randomized to Sutent, just-in-time inventory that eliminated waste and reduced the burden on the site by not having to stock Sutent inventory.
PharmaStrategies provided a win-win scenario for our Client, site and subject. Our Client saved over $5,700,000 vs. paying full price for each bottle of Sutent. An additional savings of $2,300,000 was gained by eliminating 20% product waste, for total savings in excess of $8,000,000. Our Client exceeded expectations and reached full enrollment in 23 months.
Overcoming Budgetary Constraints
Our Client faced budgetary restraints with their clinical trial. Rituxan was the Standard of Care product in a double-blinded study where the Subject received the Investigational Drug and Rituxan in one arm or the Placebo and Rituxan in the second arm.
PharmaStrategies provided the Client with an itemized line item financial forecast that illustrated substantial savings. Our distribution allowed each site to utilize their current Rituxan supplier.
PharmaStrategies provided the Client with $4,500,000 of savings vs. paying full price for each Rituxan dose and an additional savings of $1,700,000 by eliminating 20% product waste for a total savings in excess of $6,200,000.